Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6atac small nuclear 27, pseudogene (RNU6ATAC27P) is a processed pseudogene derived from U6atac small nuclear RNA, which is involved in minor spliceosome-mediated splicing of pre-messenger RNA, but the pseudogene itself does not produce a functional snRNA or protein[3][4]. Such pseudogenes are typically products of retrotransposition, displaying sequence homology to functional snRNAs yet lacking canonical gene activity[4]. Some pseudogenes, through their RNA transcripts, can exert regulatory influences by acting as microRNA decoys or sources of endogenous siRNAs, thereby modulating gene expression in trans[1][5]; however, there is no specific evidence or characterization of such functions for RNU6ATAC27P itself[3]. Pseudogenes in general are now recognized for their potential regulatory roles in gene expression, though most are not considered actionable targets in therapeutic development[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear 27, pseudogene (RNU6ATAC27P).